Overview

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Status:
Terminated
Trial end date:
2017-01-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF non-aberrant) metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Clovis Oncology, Inc.